{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:35:19Z","timestamp":1720283719196},"reference-count":51,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.vaccine.2008.08.007","type":"journal-article","created":{"date-parts":[[2008,8,22]],"date-time":"2008-08-22T10:11:31Z","timestamp":1219399891000},"page":"5554-5561","source":"Crossref","is-referenced-by-count":16,"title":["Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine"],"prefix":"10.1016","volume":"26","author":[{"given":"Christina L.","family":"Airhart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold N.","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J.","family":"Hovde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Bohach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia F.","family":"Deobald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Minnich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2008.08.007_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014etiological agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2008.08.007_bib2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/S0264-410X(02)00119-6","article-title":"Determination of the virulence of the pigmentation-deficient and pigmentation-\/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague","volume":"20","author":"Welkos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.007_bib3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0264-410X(95)00090-N","article-title":"A comparison of plague vaccine USP and EV76 vaccine induced protection against Yersiniapestis in a murine model","volume":"13","author":"Russell","year":"1995","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib4","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/IAI.64.6.2180-2187.1996","article-title":"Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge","volume":"64","author":"Andrews","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.08.007_bib5","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.vaccine.2004.10.025","article-title":"Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens","volume":"23","author":"Glynn","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2006.09.052","article-title":"Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague","volume":"25","author":"Williamson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.007_bib7","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1016\/j.vaccine.2007.09.030","article-title":"Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens","volume":"25","author":"Uddowla","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.007_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pep.2006.12.018","article-title":"Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague","volume":"53","author":"Goodin","year":"2007","journal-title":"Protein Exp Purif"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4269\/ajtmh.1998.58.793","article-title":"Short- and long-term efficacy of single dose subunit vaccines against Yersinia pestis in mice","volume":"58","author":"Anderson","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.08.007_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/mpat.2002.0498","article-title":"Anti-V antigen antibody protects macrophages from Yersinia pestis-induced cell death and promotes phagocytosis","volume":"32","author":"Weeks","year":"2002","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2008.08.007_bib11","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1021\/pr070036r","article-title":"Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-\u03b3 receptor","volume":"6","author":"Abramov","year":"2007","journal-title":"J Proteome Res"},{"issue":"8","key":"10.1016\/j.vaccine.2008.08.007_bib12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1084\/jem.20020908","article-title":"Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression","volume":"196","author":"Sing","year":"2002","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2008.08.007_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.70.3.1453-1460.2002","article-title":"Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis","volume":"70","author":"Du","year":"2002","journal-title":"Infect Immun"},{"issue":"5748","key":"10.1016\/j.vaccine.2008.08.007_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1118476","article-title":"The V-antigen of Yersinia forms a distinct structure at the tip of the injectisome needles","volume":"310","author":"Mueller","year":"2005","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2008.08.007_bib15","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1128\/IAI.73.8.5152-5159.2005","article-title":"LcrV plague vaccine with altered immunomodulatory properties","volume":"73","author":"Overheim","year":"2005","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4269\/ajtmh.1998.58.793","article-title":"Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice","volume":"58","author":"Anderson","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2008.08.007_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.micpath.2006.09.003","article-title":"Immunogenicity of the rF1+RV vaccine for plague with identification of potential immune correlates","volume":"42","author":"Williamson","year":"2007","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2008.08.007_bib18","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1016\/j.vaccine.2004.02.036","article-title":"A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague","volume":"22","author":"Wang","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.007_bib19","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/IAI.64.11.4580-4585.1996","article-title":"Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-positive and -negative strains of Yersinia pestis","volume":"64","author":"Anderson","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.08.007_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0264-410X(00)00108-0","article-title":"Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains","volume":"19","author":"Jones","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.08.007_bib21","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1016\/j.vaccine.2007.03.051","article-title":"A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1\/Th2 immune responses in mice immunized with HBsAg","volume":"25","author":"Khajuria","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2008.08.007_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2008.08.007_bib23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.vaccine.2005.09.052","article-title":"Intranasal Protollin\u2122\/V1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection","volume":"24","author":"Jones","year":"2006","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2008.08.007_bib24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.vaccine.2005.11.047","article-title":"Respiratory immunity is an important component of protection elicited by subunit vaccination against pneumonic plague","volume":"24","author":"Reed","year":"2006","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2008.08.007_bib25","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1128\/IAI.73.8.5256-5261.2005","article-title":"Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens","volume":"73","author":"Glynn","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.08.007_bib26","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1128\/IAI.71.7.3673-3681.2003","article-title":"Interleukin-10 and inhibition of innate immunity to yersiniae: roles of Yops and LcrV (V-antigen)","volume":"71","author":"Brubaker","year":"2003","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2008.08.007_bib27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1365-2958.2004.04059.x","article-title":"Variation in lipid A structure in the pathogenic yersiniae","volume":"52","author":"Rebeil","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2008.08.007_bib28","first-page":"521","article-title":"Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response","volume":"112","author":"Montminy","year":"2006","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2008.08.007_bib29","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1128\/IAI.73.5.3044-3052.2005","article-title":"Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge","volume":"73","author":"Cluff","year":"2005","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2008.08.007_bib30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib31","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1074\/jbc.M310760200","article-title":"Structure-activity relationship of synthetic Toll-like receptor 4 agonists","volume":"279","author":"Stover","year":"2004","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2008.08.007_bib32","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1099\/mic.0.2008\/017566-0","article-title":"Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague","volume":"154","author":"Airhart","year":"2008","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2008.08.007_bib33","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57Bl\/10ScCr mice: mutation in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2008.08.007_bib34","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2008.08.007_bib35","unstructured":"Geary NL. Animal models and correlates of protection for plague vaccines In: FDA Heath and Human Services Public Workshop on Animal Models and Correlates of Protection for Plague Vaccines. Gaithersburg, Maryland: FDA-Center for Biologics Evaluation and Research, 2004: p. 1\u2013300."},{"issue":"49","key":"10.1016\/j.vaccine.2008.08.007_bib36","doi-asserted-by":"crossref","first-page":"17786","DOI":"10.1073\/pnas.0506840102","article-title":"Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity","volume":"102","author":"Lathem","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib37","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.00185-06","article-title":"Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection","volume":"74","author":"Parent","year":"2006","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2008.08.007_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/IAI.00403-06","article-title":"Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice","volume":"75","author":"Bubeck","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.08.007_bib39","doi-asserted-by":"crossref","unstructured":"Human plague in 2002 and 2003. Wkly Epidem Record 2004;79(33):301\u20138.","DOI":"10.1145\/1031570.1031588"},{"key":"10.1016\/j.vaccine.2008.08.007_bib40","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/IAI.74.2.1113-1120.2006","article-title":"Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis","volume":"72","author":"Honko","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.08.007_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-409X(01)00166-1","article-title":"Intranasal vaccination against plague, tetanus, and diphtheria","volume":"51","author":"Alpar","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2008.08.007_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family","volume":"76","author":"Gessener","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vaccine.2008.08.007_bib43","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1084\/jem.142.6.1520","article-title":"Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages","volume":"142","author":"Unkeless","year":"1975","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2008.08.007_bib44","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2008.08.007_bib45","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1084\/jem.145.5.1316","article-title":"Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line","volume":"145","author":"Heusser","year":"1977","journal-title":"J Exp Med"},{"issue":"46\/47","key":"10.1016\/j.vaccine.2008.08.007_bib46","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1016\/j.vaccine.2004.09.041","article-title":"A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1\/Th2 immune response in diphtheria\u2013tetanus\u2013pertussis vaccine","volume":"23","author":"Sugai","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2008.08.007_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2008.08.007_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14712598.7.3.391","article-title":"Cervarix\u2014a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer","volume":"7","author":"Crosbie","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2008.08.007_bib49","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2008.08.007_bib50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10156-003-0263-5","article-title":"Promising immunotherapies with Th1-related cytokines against infectious diseases","volume":"9","author":"Kawakami","year":"2003","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2008.08.007_bib51","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.4049\/jimmunol.180.11.7574","article-title":"Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia","volume":"108","author":"Lembo","year":"2008","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0801075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0801075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T21:42:07Z","timestamp":1588887727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0801075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":51,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0264410X0801075X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.08.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}